Taxotere, Docetaxel Newswire (Page 4)

Taxotere, Docetaxel Newswire (Page 4)

Comprehensive Real-Time News Feed for Taxotere, Docetaxel (generic). (Page 4)

Results 61 - 80 of 773 in Taxotere, Docetaxel (generic)

  1. Royal Bank of Canada Increases Eagle Pharmaceuticals Inc (EGRX) Price Target to $94.00Read the original story w/Photo

    May 11, 2017 | Daily Political

    The firm currently has an "outperform" rating on the specialty pharmaceutical company's stock. Royal Bank of Canada's price target indicates a potential downside of 2.94% from the stock's previous close.

    Comment?

  2. Merrimack Reports First Quarter 2017 Financial ResultsRead the original story

    May 9, 2017 | BioSpace

    Completes asset sale to Ipsen for up to $1.025 billion in cash and potential milestones payments; declares special cash dividend to stockholders of $140 million Initiates Phase 1 clinical study of antibody-directed nanotherapeutic MM-310; data expected in 2018 Conference call at 8:30 am ET today "The first quarter of 2017 was transformative for Merrimack. Following our pipeline prioritization and the strategic review of our business, we emerged with clear priorities as a refocused research and clinical development company.

    Comment?

  3. Roche provides update on phase III study of TECENTRIQ (atezolizumab)...Read the original story

    May 10, 2017 | PressReleasePoint

    Roche today announced that the Phase III IMvigor211 study that evaluated TECENTRIQA in people with locally advanced or metastatic urothelial cancer whose disease progressed during or after treatment with a platinum-based chemotherapy did not meet its primary endpoint of overall survival compared to chemotherapy. The safety profile observed in IMvigor211 was consistent with what has been previously observed for TECENTRIQ.

    Comment?

  4. Genentech's Top Cancer Prospect Flunks Phase III TestRead the original story

    May 9, 2017 | BioSpace

    The safety profile observed in IMvigor211 was consistent with what has been previously observed for TECENTRIQ. "While these results are not what we had expected, we believe that TECENTRIQ will continue to play an important role in the treatment of people with advanced bladder cancer," said Sandra Horning, M.D., chief medical officer and head of Global Product Development.

    Comment?

  5. Oral Cancer Treatment Market Trend, Overview, Segment, Key Players,...Read the original story

    May 9, 2017 | World News Report

    PUNE, MAHARASHTRA, INDIA, May 9, 2017 / EINPresswire.com / -- Oral Cancer Treatment Market Information, by Types , by Drugs - Forecast to 2022 The Globally Market for Oral Cancer Treatment is one of the steady growing markets. The factors that influence the growth of the oral cancer treatment market include increasing consumption of tobacco, smoking, excessive consumption of alcohol and many others.

    Comment?

  6. Combination treatment for advanced lung cancer does not improve survivalRead the original story w/Photo

    May 9, 2017 | PhysOrg Weblog

    Among patients previously treated for a type of advanced lung cancer, use of a combination treatment did not improve progression-free or overall survival, according to a study published by JAMA . Genotype-directed targeted therapy is the standard of care for patients with advanced non-small cell lung cancer .

    Comment?

  7. Malignant Pleural Effusion Treatment Market: Industry Survey and Industry Outlook 2025Read the original story w/Photo

    May 8, 2017 | SBWire

    Mail Service Pharmacy Market: Snapshot Mail service pharmacy is swiftly becoming a highly used channel of distribution of pharmaceutical products to the consumers. Some of the leading players in the global mail service pharmacy market are propelling their services ahead of the game through high level quality improvements, addition of benefits and loyalty services, greater accountability, patient care, and consumer protection.

    Comment?

  8. BeyondSpring Pharmaceuticals Chief Medical Officer To Present At...Read the original story

    May 7, 2017 | BioSpace

    Dr. Ramon Mohanlal Speaking at the Evolution Summit in Miami, Chief Medical Officer Summit in Boston and Clinical Leader Forum in Philadelphia New York - May 8, 2017 - BeyondSpring Inc. , a global clinical stage biopharmaceutical company focused on the development of innovative cancer therapies, announced today that the Company's Chief Medical Officer and Head of Business Development, Dr. Ramon Mohanlal, M.D., Ph.D., M.B.A., will present at the Evolution Summit in Miami, Chief Medical Officer Summit in Boston and Clinical Leader Forum in Philadelphia on May 8, 10 and 11, 2017, respectively.

    Comment?

  9. BeyondSpring Chief Medical Officer to Present at Three Prominent Industry Conferences in May 2017Read the original story

    May 8, 2017 | P&T Community

    BeyondSpring Inc. , a global clinical stage biopharmaceutical company focused on the development of innovative cancer therapies, announced today that the Company's Chief Medical Officer and Head of Business Development, Dr. Ramon Mohanlal, M.D., Ph.D., M.B.A., will present at the Evolution Summit in Miami, Chief Medical Officer Summit in Boston and Clinical Leader Forum in Philadelphia on May 8, 10 and 11, 2017, respectively.

    Comment?

  10. Eagle Pharmaceuticals, Inc. Reports First Quarter 2017 ResultsRead the original story w/Photo

    Dec 31, 2016 | Business Wire

    Highlights of and subsequent to the first quarter of 2017 include: Eight new patents allowed by the U.S. Patent and Trademark Office for Eagle's Bendeka portfolio bringing the total to 14 issued or allowed, with 13 listed in the Orange Book; Granted Priority Review by the U.S. Food and Drug Administration for the Company's NDA for Ryanodex for Exertional Heat Stroke with a PDUFA target date of July 23, 2017; Appointed Richard A. Edlin to the Company's Board of Directors, and as a member of the Board's Nominating and Corporate Governance Committee; NDA for Pemetrexed Injection for non-small cell lung cancer and mesothelioma accepted for filing; PDUFA target date of October 30, 2017; and, By the end of the quarter, Eagle had purchased $51 million in Eagle common stock as part of its $75 million Share Repurchase Program.

    Comment?

  11. Gamma-glutamyltransferase activity in exosomes as a potential marker for prostate cancerRead the original story w/Photo

    May 4, 2017 | BioMed Central

    Exosomes or extracellular vesicles have the potential as a diagnostic marker for various diseases including cancer. In order to identify novel exosomal markers for prostate cancer , we performed proteomic analysis of exosomes isolated from PC cell lines and examined the usefulness of the marker in patients.

    Comment?

  12. Eagle Pharmaceuticals (EGRX) Getting Somewhat Favorable Media Coverage, Study FindsRead the original story w/Photo

    May 5, 2017 | IntersportsWire

    Press coverage about Eagle Pharmaceuticals has trended somewhat positive recently, according to AlphaOne Sentiment Analysis. AlphaOne, a service of Accern, identifies positive and negative press coverage by analyzing more than twenty million news and blog sources in real-time.

    Comment?

  13. Some lung cancer patients benefit from immunotherapy even after disease progressionRead the original story w/Photo

    May 5, 2017 | PhysOrg Weblog

    Some advanced lung cancer patients benefit from immunotherapy even after the disease has progressed as evaluated by standard criteria, according to research presented at the European Lung Cancer Conference .1 The findings pave the way for certain patients to continue treatment if the disease is not progressing according to new, more specific, criteria. The Response Evaluation Criteria in Solid Tumours evaluates changes in tumour size and identifies whether patients are responding to treatment or progressing.

    Comment?

  14. New blood test predicts who will benefit from targeted prostate cancer treatmentsRead the original story w/Photo

    May 5, 2017 | Medical News Today

    A new blood test could predict which men with advanced prostate cancer will respond to new targeted treatments for the disease. Researchers were able to detect tumour DNA in men's blood and pick out cancers with multiple copies of the androgen receptor gene, which many prostate cancers rely on to grow.

    Comment?

  15. Middle-East is expected the highest growth in MEA region for Lung Cancer Therapeutics Market.Read the original story w/Photo

    May 4, 2017 | PR-inside.com

    Middle-East and Africa Lung Cancer Therapeutics Market by Treatment Type , Radiotherapy and Other Drugs ) and by Region - Industry Analysis, Size, Share, Growth, Trends, and Forecasts In the report published by Market Data Forecast named "Middle-East and Africa Lung Cancer Therapeutics Market", the market is estimated at $0.62 billion in 2016 and poised to grow $0.86 billion by 2021 with a CAGR of 6.59% in the forecast period. Lung cancer is a malignant tumor characterized by uncontrolled growth of cell tissues in the lung.

    Comment?

  16. Easton Pharmaceuticals Announces Signing LOI For The Acquisition Of...Read the original story

    May 2, 2017 | BioSpace

    Easton Pharmaceuticals, Inc. announces it has signed an LOI for the acquisition of revenue producing, Israel based therapeutics company, Herbs of Kedem. Herbs of Kedem is an Israeli based company with sales in excess of $2,200,000 US and healthy profit margins with a current net profit of approximately $1,500,000 US with minimal marketing exposure.

    Comment?

  17. Prevalence of Life Threatening Diseases Will Drive the Growth of Nanomaterial in Theranostics MarketRead the original story w/Photo

    May 1, 2017 | PR-inside.com

    The nanomaterials in theranostics market are segmented based on type of nanomaterial namely, biological, organic and inorganic. The biological nanomaterials utilized in theranostics are proteins, antibodies.This research report analyzes this market on the basis of its market segments, major geographies, and current market trends.

    Comment?

  18. Norges Bank Invests $5.634 Million in Eagle Pharmaceuticals IncRead the original story w/Photo

    Apr 29, 2017 | IntersportsWire

    Norges Bank bought a new stake in Eagle Pharmaceuticals Inc during the fourth quarter, according to its most recent disclosure with the SEC. The fund bought 71,008 shares of the specialty pharmaceutical company's stock, valued at approximately $5,634,000.

    Comment?

  19. Eagle Pharmaceuticals (EGRX) Receiving Favorable Press Coverage, Analysis ShowsRead the original story w/Photo

    Apr 28, 2017 | IntersportsWire

    Media headlines about Eagle Pharmaceuticals have been trending positive recently, Alpha One Sentiment reports. The research firm, a service of Accern, identifies positive and negative media coverage by reviewing more than twenty million news and blog sources in real-time.

    Comment?

  20. Beyondspring Inc's Quiet Period To Expire on April 18thRead the original story w/Photo

    Apr 28, 2017 | IntersportsWire

    Beyondspring's quiet period is set to end on Tuesday, April 18th. Beyondspring had issued 174,286 shares in its IPO on March 9th.

    Comment?